Articles tagged with Liver Tumors
Researchers have developed dynamic nanoparticles that can be used as contrast agents for MRI and PET scans, deliver chemotherapy directly to tumors, and respond to light to destroy tumor cells. The particles are biocompatible, non-toxic, and can be easily made, making them a promising tool in cancer treatment.
Researchers have shown that injecting a weakened version of the anaerobic bacteria Clostridium novyi can shrink tumors in rats, dogs, and a human patient. The bacteria excise tumor tissue in a precise, localized way that spares surrounding normal tissue.
Cancer cells that break away from tumors can prefer soft environments for growth and proliferation, researchers at the University of Illinois found. The study suggests that this preference may explain why soft tissues are more vulnerable to cancer metastasis and recurrence.
A study by Mayo Clinic researchers found that the size of tumors before treatment is a strong predictor of response to immunotherapy drug MK-3475. The findings suggest that decreasing baseline tumor size through surgery or other means may be more effective in inducing long-lasting remissions.
A University of Colorado Cancer Center study identifies AGL as a key driver of bladder cancer growth, linked to hereditary liver disease glycogen storage disease 3. Low AGL levels correlate with poorer prognosis and increased tumor proliferation.
Researchers at Johns Hopkins Medicine have developed a new technology that uses 3D MRI scans to precisely measure living and dying tumor tissue, allowing for more accurate predictions of patient survival after chemotherapy. The technology has been shown to improve survival rates by up to 19 months in patients with liver tumors.
A new treatment option for metastatic breast cancer patients with liver metastases shows promise in slowing disease progression and improving quality of life. Yttrium-90 radioembolization was safe and provided disease stabilization in 98.5% of treated liver tumors, with many experiencing significant tumor shrinkage.
Researchers discovered an unusual genetic mutation in patients with fibrolamellar hepatocellular carcinoma, a rare and aggressive form of liver cancer. The mutated gene, called a chimera, is constantly active and drives the growth of tumor cells.
Researchers at the University of Michigan found that mice exposed to BPA via their mothers developed liver tumors and precancerous lesions. The study suggests a significant association between BPA and cancer development, with findings that may have implications for human health.
Researchers developed a gene delivery method targeting tumor blood vessels in mice, avoiding healthy tissues. The approach uses a deactivated virus carrying a gene of interest to hijack abnormal blood vessels and alter the tumor microenvironment.
Researchers identified a molecular link between liver cancer, cellular stress and health problems that increase the risk of developing this cancer. The protein CHOP promotes liver cancer in mice and may do so in humans too.
Researchers at the University of Manchester have developed a novel technique for reprogramming somatic cells into induced pluripotent stem (iPS) cells without using viruses, reducing the risk of tumor formation. This breakthrough could revolutionize regenerative medicine and provide new hope for treating various diseases.
A study by IDIBELL researchers has identified a mechanism inducing tumor cell migration in liver cancer, suggesting that patients with overactivated TGFb and high CXCR4 levels may benefit from TGFb inhibitory therapy. The findings provide new insights into the molecular mechanisms underlying liver cancer progression.
For the first time, researchers have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma (HCC) tumors. These cells can be identified long before actual tumors are apparent, suggesting a new approach for early detection and therapeutic intervention.
Researchers Dr. Joan Seoane and Dr. Eduard Batlle from Barcelona have been recognized for their outstanding contributions to cancer research, with a focus on brain cancer and colorectal tumors. Their work aims to identify tumor stem cells and develop new therapeutic strategies to block metastasis.
Researchers found that consuming soy peptide lunasin orally reduced the number of metastatic tumors in mice with human colon cancer cells. The highest dose of 20 mg/kg of lunasin achieved a 94% reduction in tumors, showing promise for new cancer treatment approaches.
Researchers found TP53 as the most commonly mutated tumor suppressor gene in hepatocellular carcinoma, leading to poor survival outcomes. The study also identified the Wnt/β-Catenin signaling pathway as a major oncogenic driver in liver cancer.
Researchers at Columbia University Medical Center have identified hundreds of metabolic expression changes and potential drug targets to cut off a tumor's fuel supply. The study, published in Nature Biotechnology, provides a comprehensive view of diverse metabolic alterations in cancer, shedding light on how tumors adapt their metaboli...
A new minimally invasive tumor ablation technique called irreversible electroporation (IRE) has shown promising results in treating liver cancer patients who cannot undergo surgery or thermal ablation. The study found that IRE successfully destroyed tumor tissue in 70% of patients, with two major complications reported but neither life...
A new electrical pulse treatment called irreversible electroporation (IRE) has been shown to be safe and effective for treating complex cancers without harming healthy tissue. IRE precisely perforates cancer cells, posing fewer risks to vital structures.
Researchers have discovered that mutations in the TERT promoter gene are involved in some brain tumors and certain types of cancer. The study found nine tumor types highly associated with these mutations, which may provide a new target for drug development.
Scientists at Washington University School of Medicine identified a mutated gene, SF3B1, in eye melanoma tumors that predict a good outcome. The mutation is found in a distinct subtype of melanomas unlikely to spread and become deadly.
Researchers at Johns Hopkins Medicine developed a method to track liver tumors' response to chemotherapy using paired CT scans, allowing for immediate feedback on treatment effectiveness. This technique has the potential to save patients from delayed diagnosis and reduced treatment efficacy.
A study by the University of Colorado Anschutz Medical Campus suggests that a healthy lifestyle during menopause, including diet and exercise, can lower breast cancer risk. In obese postmenopausal women, excess calories fuel tumor growth, but in lean counterparts, they are stored in healthy tissues.
A new gene delivery vehicle has been developed to target tumor cells with the TNFα cytokine, allowing for improved drug delivery and reduced resistance. The treatment approach combines the cytokine with a DNA-intercalating drug doxorubicin, showing promise in reducing tumor growth and metastasis.
A new formulation of cisplatin has been developed to improve the effectiveness and safety of cancer treatment. The pH-sensitive liposome was able to reduce cancer cell proliferation and increase survival in animal models with no known toxicity clinical signs.
A recent study found that miR-122 is involved in modulating fat and cholesterol metabolism in the liver. Additionally, it may have a tumor suppressive function in hepatocytes, suggesting its potential as a therapeutic target for hepatocellular carcinoma. The molecule's role in liver homeostasis has also been highlighted.
A new treatment protocol that includes accurate CT scan analysis and complex surgical technique has significantly increased long-term survival for patients with previously inoperable pancreatic adenocarcinoma. On average, patients lived about 30 months after tumor removal, nearly three times longer than those who never underwent surgery.
Studies using specialized MRI scans show that the procedure can detect whether anti-cancer chemotherapy is working, buying patients many months to a year of life. The scans use software to analyze water movement in tumor cells, identifying those with high and low apparent diffusion coefficients.
Researchers at University of Leeds and The Institute of Cancer Research have made breakthrough with a viral therapy that attacks cancer on two fronts. This 'hitch-hiking' virus can be injected into the bloodstream like standard chemotherapy agents, targeting cancer cells while leaving normal tissue alone.
Research reveals that commonly occurring large chromosomal deletions contain areas with multiple functionally linked genes whose loss confers a survival advantage on tumors. The study validated the presence of these linked genes in mouse models of human liver cancer and demonstrated their cooperative action.
Researchers at Mayo Clinic have made significant breakthroughs in developing a new melanoma vaccine that uses a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. Early studies show a cure rate of 60% in mouse models with minimal side effects. The vaccine delivers a broad spectrum of genes derived fr...
Researchers have discovered a new target for cancer therapy, TDO enzyme, which enables tumors to evade immune rejection. A novel inhibitor of TDO has shown promising results in preclinical studies.
A novel molecular process linked to neddylation has been found to be involved in the development of hepatocellular carcinoma, a type of liver cancer with poor prognosis. The study suggests that targeting this process could lead to potential therapeutic applications for patients with HCC.
Researchers discovered that topical application of imiquimod recruits plasmacytoid DCs to the tumor site, converting them into tumor-killing effector cells. A new mechanism for IFN-alpha suppression was also identified, targeting epigenetic regulation of nuclear cccDNA minichromosome.
Researchers found that 2-deoxyglucose reduces tumor size in mice on either diet, while a carbohydrate-free diet led to greater tumor growth. This combination imposes energy stress on tumors and correlates with lower serum glucose levels.
Two new studies advance the field of yttrium-90 radioembolization for liver cancer treatment. Researchers successfully modified blood vessels to maximize tumor-killing material delivery and simplify treatment. This technique allows for high local radiation doses with minimal risk to healthy tissues.
Researchers tested a combination of oral drug sorafenib and microbead chemotherapy directly into tumors in advanced liver cancer patients. The treatment showed promise with no increased side effects compared to existing therapies.
An international research team has shown that an investigational agent that sticks onto the surface of tumor cells can effectively image tumors. The 'antagonist', 111In-DOTA-BASS, outperformed the widely used 'agonist' agent, OctreoScan, in detecting neuroendocrine tumors.
A European study found radioembolization to be a viable treatment option for liver cancer patients, with median overall survival near 13 months. The procedure improved survival rates across different tumor stages and in patients with few treatment options.
A new imaging technology reveals that metabolic shifts in cancer cells occur even before detectable tumors form, suggesting an early diagnostic tool for liver cancer. The study also shows that tumor metabolism changes precede tumor regression, offering potential strategies for cancer treatment and more effective therapies.
A team of researchers from Brown University has developed a new technique using gold nanoparticles to detect liver cancer at early stages. The approach uses X-ray scatter imaging to spot tumor-like masses as small as 5 millimeters, which is significantly smaller than the current detection limit of about 5 centimeters.
Researchers at Dana-Farber Cancer Institute conducted a phase 1 clinical trial using ipilimumab and bevacizumab to treat advanced, inoperable melanomas. The trial showed that the combination of these two drugs was safe and potentially more effective than either drug alone.
Researchers create engineered mesoporous silica nanoparticles that improve drug delivery to tumors, increasing particle retention by up to 10% and reducing systemic side effects. The optimized platform achieves significant increases in doxorubicin delivery, inducing tumor shrinkage and apoptosis while improving safety profiles.
A four-year study confirms that Y-90 radioembolization is a safe and effective treatment for patients with metastatic liver cancer, particularly those who have failed chemotherapy. The procedure preserves patient quality of life and extends life, while also demonstrating anti-tumoral effects.
Researchers are using genetically modified salmonella packaged with Interlueken 2 to create a two-prong attack on cancer. The therapy, administered orally, shows promise in controlling tumors in the gut and may offer a cheaper and less toxic alternative to chemotherapy and radiation.
A Phase III trial found that everolimus significantly improved progression-free survival for patients with advanced pancreatic neuroendocrine tumors, reducing the risk by 65% and increasing median progression-free survival by over six months. Common side effects include stomatitis, rash, diarrhea, fatigue, and infections.
Researchers found that high levels of a particular protein in cancer cells can predict cancer spread with high accuracy. The protein, CPE-delta N, was measured in tumors and surrounding tissues from patients with liver and rare tumors, with results showing that it can accurately predict metastasis or recurrence.
Researchers at Thomas Jefferson University developed a new real-time tumor tracking technique that minimizes radiation delivery to surrounding healthy tissue by up to 50%. This approach enables radiation oncologists to administer more radiation and faster to tumors, potentially decreasing side effects.
Researchers found that N-acetylcysteine can decrease the size of von Willebrand factor multimers in mice, potentially treating life-threatening blood disorder thrombotic thrombocytopenic purpura (TTP). However, chronic use of drugs targeting Notch1 raises concerns due to its link to vascular tumors and lethal hemorrhage in mice.
Researchers found radiofrequency ablation to be a safe and effective therapy for managing hepatocellular carcinoma in cirrhotic patients. The procedure resulted in high complete response rates, with 98.5% of patients achieving disease-free status.
A study found that high circulating tumor cells (CTCs) are an independent prognostic marker for poor overall survival in metastatic breast cancer patients undergoing first-line chemotherapy. Persistence of high CTC levels during therapy was also an early marker of poor outcome.
A new dendritic cell vaccine has been developed at Dartmouth Health, which uses the patient's own tumor cells to stimulate an anti-tumor response. The study found that over 60% of patients who received the vaccine developed immune responses against their tumors, with a significant survival rate five years after treatment.
A new study found that many pancreatic tumors are slow-growing, taking nearly 20 years to become lethal after the first genetic perturbations appear. This challenges previous theories and suggests a potential window of opportunity for early diagnosis and treatment.
Researchers at UT MD Anderson Cancer Center found that TAp63, a tumor-suppressing protein, blocks cancer spread by activating Dicer and miR-130b. This discovery has far-reaching implications for understanding cancer development and metastasis.
Researchers found FSH receptor present in all cancer tumour samples, regardless of type or stage. The discovery highlights the potential of this receptor as a target for anti-cancer drugs and imaging procedures.
Mount Sinai researchers discovered a hormone receptor linked to several malignant tumor types, suggesting a new diagnostic or therapeutic target. The receptor's presence may be used to improve cancer detection and develop imaging agents that can visualize early tumors.
Research suggests a potential viral link between HCMV and intestinal cancer in mice, where infected cells develop tumors. Meanwhile, scientists identify a key protein regulating breathing in mice and explore survivin as an anticancer target.
The Journal of Vascular and Interventional Radiology's August supplement explores the development of thermal ablation techniques and devices for cancer tumor ablation. Key findings include advancements in liquid nitrogen-based cryotherapy, microwave devices, and magnetic resonance-guided focused ultrasound.
Researchers at Columbia University have found that ROCK2 may be a good therapeutic target for treating autoimmune disorders, while targeting CD13+ CSCs in liver cancer could provide a new treatment approach. Additionally, scientists at Stanford University developed ways to enhance RNAi efficacy and persistence while decreasing toxicity.